Research progress in cytopenia after CAR-T cell therapy for hematological malignancies
-
摘要: 嵌合抗原受体(CAR)T细胞在血液肿瘤治疗中的有效性得到广泛认可。CAR-T相关不良反应有细胞因子释放综合征(cytokine release syndrome，CRS)、免疫效应细胞相关神经毒性综合征和血液学毒性。CAR-T后血液学毒性是多发性骨髓瘤、B细胞淋巴瘤、急性白血病患者中最常见的3级以上不良反应，受CRS反应及相关细胞因子、骨髓功能、CAR-T结构、清淋化疗、基线血细胞、铁蛋白峰值、既往治疗线数、造血干细胞移植状态等影响。血液学毒性影响患者预后，缩短无进展生存期、总生存期，增加感染风险以及死亡率。CAR-T输注前可使用CAR-HEMATOTOX评分模型进行基线风险评估，输注后可根据最新发表的CAR-T相关血液学毒性(ICAHT)共识进行ICAHT分级管理，以期提高患者生存率，改善预后。Abstract: The effectiveness of chimeric antigen receptor(CAR) T cells in the treatment of hematological tumors is obvious. CAR-T related adverse effects include cytokine release syndrome(CRS), immune effector cell associated neurotoxicity syndrome, and hematological toxicity. Hematological toxicity after CAR-T is the most common grade 3 or higher adverse event in patients with multiple myeloma, B-cell lymphoma, and acute leukemia. It is influenced by CRS and CRS related cytokines, bone marrow function, CAR-T structure, lymphodepletion chemotherapy, baseline absolute neutrophil count(ANC), baseline hemoglobin(Hb), baseline platelet, ferritin peak, previous therapy lines and previous hematopoietic stem cell transplantation. Hematologic toxicity affects the prognosis of patients, shortens progression free survival and overall survival, increases the risk of infection and mortality. Before CAR-T infusion, the CAR-HEMATOTOX scoring model could be used for evaluating hematologic toxicity. After infusion, ICAHT grading management could be carried out according to the latest published consensus on CAR-T related hematotoxicity(ICAHT), to improve the survival and prognosis of patient.
-
Key words:
- chimeric antigen receptor T cell /
- hematological malignancies /
- cytopenias
-
-
[1] Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity[J]. Proc Natl Acad Sci U S A, 1989, 86(24): 10024-10028. doi: 10.1073/pnas.86.24.10024
[2] Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia[J]. N Engl J Med, 2011, 365(8): 725-733. doi: 10.1056/NEJMoa1103849
[3] Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med, 2014, 371(16): 1507-1517. doi: 10.1056/NEJMoa1407222
[4] Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial[J]. Lancet, 2015, 385(9967): 517-528. doi: 10.1016/S0140-6736(14)61403-3
[5] Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia[J]. N Engl J Med, 2018, 378(5): 439-448. doi: 10.1056/NEJMoa1709866
[6] Locke FL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma[J]. N Engl J Med, 2022, 386(7): 640-654. doi: 10.1056/NEJMoa2116133
[7] Schuster SJ, Bishop MR, Tam CS, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma[J]. N Engl J Med, 2019, 380(1): 45-56. doi: 10.1056/NEJMoa1804980
[8] Abramson JS, Palomba ML, Gordon LI, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas(TRANSCEND NHL 001): a multicentre seamless design study[J]. Lancet, 2020, 396(10254): 839-852. doi: 10.1016/S0140-6736(20)31366-0
[9] Fowler NH, Dickinson M, Dreyling M, et al. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial[J]. Nat Med, 2022, 28(2): 325-332. doi: 10.1038/s41591-021-01622-0
[10] Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma[J]. N Engl J Med, 2020, 382(14): 1331-1342. doi: 10.1056/NEJMoa1914347
[11] Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma(CAR-TITUDE-1): a phase 1b/2 open-label study[J]. Lancet, 2021, 398(10297): 314-324. doi: 10.1016/S0140-6736(21)00933-8
[12] Munshi NC, Anderson LD, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma[J]. N Engl J Med, 2021, 384(8): 705-716. doi: 10.1056/NEJMoa2024850
[13] Zhao WH, Liu J, Wang BY, et al. A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma[J]. J Hematol Oncol, 2018, 11(1): 141. doi: 10.1186/s13045-018-0681-6
[14] Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma[J]. J Clin Oncol, 2018, 36(22): 2267-2280. doi: 10.1200/JCO.2018.77.8084
[15] Cui Q, Qian C, Xu N, et al. CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation[J]. J Hematol Oncol, 2021, 14(1): 82. doi: 10.1186/s13045-021-01092-4
[16] Kenderian SS, Ruella M, Shestova O, et al. CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia[J]. Leukemia, 2015, 29(8): 1637-1647. doi: 10.1038/leu.2015.52
[17] Pan J, Tan Y, Wang G, et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase Ⅰ trial[J]. J Clin Oncol, 2021, 39(30): 3340-3351. doi: 10.1200/JCO.21.00389
[18] Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor(CAR)T-cell therapy[J]. Ann Oncol, 2021, 32(1): 34-48. doi: 10.1016/j.annonc.2020.10.478
[19] Xiang X, He Q, Ou Y, et al. Efficacy and safety of CAR-modified T cell therapy in patients with relapsed or refractory multiple myeloma: a meta-analysis of prospective clinical trials[J]. Front Pharmacol, 2020, 11: 544754. doi: 10.3389/fphar.2020.544754
[20] Locke FL, Ghobadi A, Jacobson CA, et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma(ZUMA-1): a single-arm, multicentre, phase 1-2 trial[J]. Lancet Oncol, 2019, 20(1): 31-42. doi: 10.1016/S1470-2045(18)30864-7
[21] Logue JM, Zucchetti E, Bachmeier CA, et al. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma[J]. Haematologica, 2021, 106(4): 978-986.
[22] Fried S, Avigdor A, Bielorai B, et al. Early and late hematologic toxicity following CD19 CAR-T cells[J]. Bone Marrow Transplant, 2019, 54(10): 1643-1650. doi: 10.1038/s41409-019-0487-3
[23] Rejeski K, Perez A, Sesques P, et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma[J]. Blood, 2021, 138(24): 2499-2513. doi: 10.1182/blood.2020010543
[24] Neelapu SS, Dickinson M, Munoz J, et al. Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial[J]. Nat Med, 2022, 28(4): 735-742. doi: 10.1038/s41591-022-01731-4
[25] Jacobson CA, Chavez JC, Sehgal AR, et al. Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma(ZUMA-5): a single-arm, multicentre, phase 2 trial[J]. Lancet Oncol, 2022, 23(1): 91-103. doi: 10.1016/S1470-2045(21)00591-X
[26] Gauthier J, Gazeau N, Hirayama AV, et al. Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL[J]. Blood, 2022, 139(26): 3722-3731. doi: 10.1182/blood.2021014497
[27] Sesques P, Ferrant E, Safar V, et al. Commercial anti-CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center[J]. Am J Hematol, 2020, 95(11): 1324-1333. doi: 10.1002/ajh.25951
[28] 李阳玉, 薛磊, 汪敏, 等. CAR-T细胞治疗复发/难治急性B淋巴细胞白血病后免疫功能的变化及其相关因素分析[J]. 临床血液学杂志, 2022, 35(5): 348-353. https://lcxy.whuhzzs.com/article/doi/10.13201/j.issn.1004-2806.2022.05.010
[29] Wang L, Hong R, Zhou L, et al. New-onset severe cytopenia after CAR-T cell therapy: analysis of 76 patients with relapsed or refractory acute lymphoblastic leukemia[J]. Front Oncol, 2021, 11: 702644. doi: 10.3389/fonc.2021.702644
[30] Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study[J]. Lancet, 2021, 398(10299): 491-502. doi: 10.1016/S0140-6736(21)01222-8
[31] Qi Y, Zhao M, Hu Y, et al. Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL[J]. Blood, 2022, 139(23): 3376-3386. doi: 10.1182/blood.2021013733
[32] Tan Y, Shan L, Zhao L, et al. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia[J]. J Hematol Oncol, 2023, 16(1): 34. doi: 10.1186/s13045-023-01427-3
[33] Zhang M, Chen D, Fu X, et al. Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia/lymphoma[J]. Clin Cancer Res, 2022, 28(13): 2830-2843. doi: 10.1158/1078-0432.CCR-21-4097
[34] Hill LC, Rouce RH, Smith TS, et al. Safety and anti-tumor activity of CD5 CAR T-cells in patients with relapsed/refractory T-cell malignancies[J]. Blood, 2019, 134: 199.
[35] Wang QS, Wang Y, Lv HY, et al. Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia[J]. Mol Ther, 2015, 23(1): 184-191. doi: 10.1038/mt.2014.164
[36] Jin X, Zhang M, Sun R, et al. First-in-human phase Ⅰ study of CLL-1 CAR-T cells in adults with relapsed/refractory acute myeloid leukemia[J]. J Hematol Oncol, 2022, 15(1): 88. doi: 10.1186/s13045-022-01308-1
[37] Zhang H, Wang P, Li Z, et al. Anti-CLL1 chimeric antigen receptor T-cell therapy in children with relapsed/refractory acute myeloid leukemia[J]. Clin Cancer Res, 2021, 27(13): 3549-3555. doi: 10.1158/1078-0432.CCR-20-4543
[38] Gill S, Tasian SK, Ruella M, et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells[J]. Blood, 2014, 123(15): 2343-2354. doi: 10.1182/blood-2013-09-529537
[39] Yao S, Jianlin C, Yarong L, et al. Donor-derived CD123-targeted CAR T cell serves as a RIC regimen for haploidentical transplantation in a patient with FUS-ERG+AML[J]. Front Oncol, 2019, 9: 1358. doi: 10.3389/fonc.2019.01358
[40] 夏洁云, 徐开林. GPRC5D CAR-T细胞治疗复发/难治性多发性骨髓瘤: 单臂Ⅱ期临床试验[J]. 临床血液学杂志, 2023, 36(7): 477-481. https://lcxy.whuhzzs.com/article/doi/10.13201/j.issn.1004-2806.2023.07.005
[41] Yan Z, Cao J, Cheng H, et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial[J]. Lancet Haematol, 2019, 6(10): e521-e529. doi: 10.1016/S2352-3026(19)30115-2
[42] Raje N, Berdeja J, Lin Y, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma[J]. N Engl J Med, 2019, 380(18): 1726-1737. doi: 10.1056/NEJMoa1817226
[43] Li H, Zhao L, Sun Z, et al. Prolonged hematological toxicity in patients receiving BCMA/CD19 CAR-T-cell therapy for relapsed or refractory multiple myeloma[J]. Front Immunol, 2022, 13: 1019548. doi: 10.3389/fimmu.2022.1019548
[44] Wang L, Hong R, Zhou L, et al. Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy[J]. Cytotherapy, 2023, 25(2): 192-201. doi: 10.1016/j.jcyt.2022.11.001
[45] Penack O, Peczynski C, Koenecke C, et al. Severe cytopenia after CD19 CAR T-cell therapy: a retrospective study from the EBMT transplant complications working party[J]. J Immunother Cancer, 2023, 11(4): e006406. doi: 10.1136/jitc-2022-006406
[46] Rejeski K, Hansen DK, Bansal R, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma[J]. J Hematol Oncol, 2023, 16(1): 88. doi: 10.1186/s13045-023-01465-x
[47] 卫延辉, 郭学军. 嵌合抗原受体T细胞治疗血液系统恶性肿瘤相关毒性机制研究进展[J]. 新乡医学院学报, 2020, 37(4): 397-401. https://www.cnki.com.cn/Article/CJFDTOTAL-XXYX202004026.htm
[48] Jain T, Knezevic A, Pennisi M, et al. Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies[J]. Blood Adv, 2020, 4(15): 3776-3787. doi: 10.1182/bloodadvances.2020002509
[49] Juluri KR, Wu QV, Voutsinas J, et al. Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy[J]. Blood Adv, 2022, 6(7): 2055-2068. doi: 10.1182/bloodadvances.2020004142
[50] Nagle SJ, Murphree C, Raess PW, et al. Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies[J]. Am J Hematol, 2021, 96(4): 455-461. doi: 10.1002/ajh.26113
[51] Li Z, Que Y, Wang D, et al. Recovery-model: a model for CAR T-cell-related thrombocytopenia in relapsed/refractory multiple myeloma[J]. Thromb Res, 2023, 227: 62-70. doi: 10.1016/j.thromres.2023.05.016
[52] Giudice V, Cardamone C, Triggiani M, et al. Bone marrow failure syndromes, overlapping diseases with a common cytokine signature[J]. Int J Mol Sci, 2021, 22(2): 705. doi: 10.3390/ijms22020705
[53] Si X, Gu T, Liu L, et al. Hematologic cytopenia post CAR T cell therapy: etiology, potential mechanisms and perspective[J]. Cancer Lett, 2022, 550: 215920. doi: 10.1016/j.canlet.2022.215920
[54] Tam CS, O'brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia[J]. Blood, 2008, 112(4): 975-980. doi: 10.1182/blood-2008-02-140582
[55] Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management[J]. Blood, 2016, 127(26): 3321-3330. doi: 10.1182/blood-2016-04-703751
[56] Luo W, Li C, Zhang Y, et al. Adverse effects in hematologic malignancies treated with chimeric antigen receptor(CAR)T cell therapy: a systematic review and Meta-analysis[J]. BMC Cancer, 2022, 22(1): 98. doi: 10.1186/s12885-021-09102-x
[57] Xia Y, Zhang J, Li J, et al. Cytopenias following anti-CD19 chimeric antigen receptor(CAR)T cell therapy: a systematic analysis for contributing factors[J]. Ann Med, 2022, 54(1): 2951-2965.
[58] Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy[J]. Blood, 2017, 130(21): 2295-2306. doi: 10.1182/blood-2017-06-793141
[59] Schubert ML, Dietrich S, Stilgenbauer S, et al. Feasibility and safety of CD19 chimeric antigen receptor T cell treatment for B cell lymphoma relapse after allogeneic hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2020, 26(9): 1575-1580. doi: 10.1016/j.bbmt.2020.04.025
[60] Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018, 15(1): 47-62. doi: 10.1038/nrclinonc.2017.148
[61] Neelapu SS. Managing the toxicities of CAR T-cell therapy[J]. Hematol Oncol, 2019, 37(S1): 48-52. doi: 10.1002/hon.2595
[62] 王玉洁, 王桃, 杨建民. 嵌合抗原受体T细胞免疫疗法预处理方案的研究进展[J]. 国际输血及血液学杂志, 2020, 43(1): 77-81.
[63] Lin Q, Liu X, Han L, et al. Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA-CAR-T therapy in patient with relapsed myeloma[J]. Bone Marrow Transplant, 2020, 55(6): 1203-1205. doi: 10.1038/s41409-019-0674-2
[64] Qiu L, Zhu F, Wei G, et al. Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy[J]. Regen Ther, 2020, 14: 271-274. doi: 10.1016/j.reth.2020.03.005
[65] Baur R, Jitschin R, Kharboutli S, et al. Thrombopoietin receptor agonists for acquired thrombocytopenia following anti-CD19 CAR-T-cell therapy: a case report[J]. J Immunother Cancer, 2021, 9(7): e002721.
[66] Rejeski K, Subklewe M, Aljurf M, et al. Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations[J]. Blood, 2023, 142(10): 865-877. doi: 10.1182/blood.2023020578
[67] Drillet G, Lhomme F, De Guibert S, et al. Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists[J]. Blood Adv, 2023, 7(4): 537-540. doi: 10.1182/bloodadvances.2022008066
[68] Taneja A, Jain T. CAR-T-OPENIA: chimeric antigen receptor T-cell therapy-associated cytopenias[J]. EJHaem, 2022, 3(S1): 32-38. doi: 10.1002/jha2.350
-
计量
- 文章访问数: 261
- 施引文献: 0
下载: